

Summit Therapeutics plc

("Summit", or the "Company")

SUMMIT THERAPEUTICS TO PARTICIPATE IN JMP SECURITIES LIFE SCIENCES CONFERENCE

Oxford, UK, 15 June 2017– Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and *Clostridium difficile* infection, announces that Glyn Edwards, CEO of Summit, will participate in a DMD pipeline panel discussion at the JMP Securities Life Sciences Conference on 21 June 2017 at 8:30am EDT in New York City.

In addition, Summit will hold one-on-one meetings at the conference. There will be no webcast of the panel.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, *Clostridium difficile* infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics

Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)

Tel: +44 (0)1235 443 951
+1 617 225 4455

Cairn Financial Advisers LLP

(Nominated Adviser)
Liam Murray / Tony Rawlinson

Tel: +44 (0)20 7213 0880

N+1 Singer

(Broker)
Aubrey Powell / Lauren Kettle

Tel: +44 (0)20 7496 3000

MacDougall Biomedical Communications

(US media contact)
Karen Sharma

Tel: +1 781 235 3060
ksharma@macbiocom.com

Consilium Strategic Communications

(Financial public relations, UK)
Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Lindsey Neville

Tel: +44 (0)20 3709 5700
summit@consilium-comms.com

-END-